3月25日，在亚洲青年领袖论坛健康与医疗主题论坛上，印度尼西亚Etana生物科技公司总裁内森·蒂尔塔纳发表主旨演讲。
全文如下：
大家下午好！非常高兴再次来到中国，距离上次来中国已经过了好一段时间了。非常高兴能够参与这次论坛，也很荣幸。正如论坛主题所言，我们来到这里是为了“增强青年合作，凝聚共同价值，促进亚洲和平与发展”，我们也在这么努力，在医疗与健康方面。
这是Etana的一些基本情况：我们位于雅加达，于2014年创立，大概是去年建了一个新的工厂，我们是印尼第二家疫苗公司。印尼只有三家疫苗公司，我们是三家之一。可以看到，印尼的生物制药公司并不多。我们主要从事生物制品、疫苗、治疗药物，这是我们目前的项目。我们已经建好了mRNA疫苗的生产设施，这是东南亚首个mRNA疫苗生产设施。我们和苏州艾博生物医药以及云南沃森开展了合作。同时，我们在开设更多工厂。大家可以看到图上标英文字母F的地方，我们今年会在这里建一个单克隆抗体的生产设施，这是和苏州信达生物制药集团合作的。我们还会建一个针对腺病毒的生产设施，这是和康希诺合作的，我们会共同开展结核病疫苗和IDO疫苗的研发。
我们之所以这么做，是为了支持2016年第六号总统令。印尼在过去5年经历了什么？发生了许多变化。2017年，印尼首次实施了全国医疗报销项目。此前，只有10%的人有机会使用医疗服务，此后，将近99%的人得以获得医疗服务。这是印尼政府做的一个非常大的重要决定，为医疗保健创造了许多机会。其实不仅仅是创造机会，还提升了整个国家的医疗保健水平。我们也雇用了许多来自全球高校的人员。
我们为什么从事生物制药？我在中国生活了10年，我第一次到中国是2002年，每年至少会来中国一次，除了新冠疫情期间没有来中国。我经历了中国发展医疗保健的情况，我仍然记得那是2002年，我可以说，2002年的中国和现在的印尼很相似，真的很相似，但中国实际上付出了巨大的努力。中国有很多生物制药公司，并且这些公司持续创新。在新的标准治疗方面，大多数的新药，50%都是生物制品。在印尼，有250多家制药企业，只有三家是生物制药企业，这是一个大问题。大家看这个表格，这是全球50大最畅销药品，56%是生物药品，而在印尼，100大畅销药品里，只有2款是生物药品。为什么会这样？这说明，印尼在标准治疗方面的水平还比较低，这就是Etana可以发挥作用的地方。我们希望能提供负担得起的生物医药产品，以此来提升印尼的医疗保健。我们除了关注印尼市场，在我们的生产设施建好以后，我们还会进入东盟、伊斯兰合作组织，这个组织有57个成员国，覆盖了19亿人。
印尼还处于医疗保健的新兴阶段。印尼拥有3亿居民，由于出台了医疗报销项目，所有居民都可以便利获得医疗保健服务。这是政府作为的结果，这在印尼起到了很大的作用。由于全球的新冠肺炎疫情，我们了解到，要进口一些关键产品很困难，这就是印尼自主实施了许多规章去推动本地生产的原因。只要你愿意在印尼进行本地生产，政府就会去支持。国家政府会优先采购在印尼生产的产品，除非本地没有，才会从国外采购。这实际上给在印尼进行本地生产创造了很多机会。在营商复杂性方面，仍然面临很大挑战：印尼在这方面仍然排在全球第二。我们正从事的行业——生物制药，特点就是高科技、高研发成本、高专业知识需求，这也是为什么我们需要和来自中国和韩国的企业合作，这些企业能给我们提供培训和技术转移，我们才能够实现在印尼生产。
因为印尼政府在促进本土制药方面作出了很大的转变，这也创造了很大的机会。只要是在印尼生产的，政府就会采购。而且不仅仅是采购，政府还可以将这个产品纳入到全国医疗报销项目里，这么一来，所有的公立医院都能使用。因此，这在行业里的确是产生了很大变化。
Etana的目标是什么？Etana在做什么？我们正在生产许多生物药品，主要是疫苗和治疗药品。我们希望能降低印尼每一款生物药品的进口度，实现印尼生产。我们会与中国公司、韩国公司合作，开展技术转移，在印尼设厂生产，将药品销售到印尼还有东南亚国家，这是我们要去实现的三个大目标。目前， mRNA疫苗生产设施即将完工。我们也在建造腺病毒相关的设施，这是和康希诺合作的。我们还在建造印尼最大的哺乳动物细胞生产设施，用于生产肿瘤相关产品和激素产品，这是和信达合作的。
最后，由于印尼是一个伊斯兰国家，我们也非常重视生产设施的清真。这会让印尼的居民放心地去使用我们的产品，同时也为我们将产品出口到全世界的伊斯兰国家创造了机会。
感谢给我提供这个机会。很高兴能在广州见到大家。
Nathan Tirtana says Etana is dedicated to advancing health care through biopharmaceutical development
On 25 March, Nathan Tirtana, CEO of Etana Biotechnologies Indonesia, delivered a keynote speech at the Health and Medical Care Forum of the Asia Youth Leaders Forum. Following is the full text of the speech.
Good afternoon, everybody. It’s glad again to be back to China. It’s been a while. I could not come to China. So, I’m very glad to be able to actually join you in this forum. It’s a great pleasure. It’s quite an honor for me to be in this Asia Youth Leaders Forum. Also as mentioned in the theme, we are here to “enhance youth cooperation, strengthen common values, and promote the peace and development of Asia”, and we do, here in the medical and health care.
Just a quick overview about Etana. We are located in Jakarta. We actually started in 2014. The factory was just inaugurated about last year. We are actually the second vaccine company in Indonesia. Only three vaccine companies in Indonesia. We are also one of the three biopharmaceutical companies in Indonesia, so there are not too many biopharmaceutical companies in Indonesia. We only focus on biologics: we focus on vaccine; we also focus on therapeutic drugs. At the moment, this is our facility. We’ve already completed the production facility for mRNA. This is actually the first mRNA production facility in Southeast Asia. We’re working with a company called Abogen, or in China it is called Suzhou Aibo, and also a company called Wosen, Yunnan Wosen. We’re also in the progress of opening more factories. If you see in the F, we’re also going to build this year monoclonal antibody production working with the company from Suzhou, called Suzhou Xinda in Chinese. We’re also going to build a new production facility for adenovirus, working with a company called CanSino in China, where we’re actually going to do R&D in TB vaccine and also IDO vaccine.
We did this to support the Presidential Instruction No. 6 of 2016. What happened in Indonesia in the last 5 years? There was a lot of changes. For the first time in Indonesia in 2017, we actually just implemented a national health reimbursement. Before 2017, only 10% have access to health care. After 2017, almost 99% have access to health care. So, it was actually one of the biggest dramatic decisions done by our government, and it really created a lot of opportunities for health care. Not just creating opportunities, it really improved the health care of our nation. We do employ a lot of people from different universities all over the world.
Why do we focus on biopharmaceuticals? I lived in China for almost ten years. I first arrived in China in 2002, and I always go to China at least once a year. Only in Covid, I didn’t come to China. I experienced how China developed in terms of health care, I still remember, in 2002. I can say 2002 in China is very similar to what Indonesia is right now, very similar, but China actually made tremendous development. Because they have so many biopharmaceutical companies that actually keep innovating. If you see in terms of the new standard treatment right now, most of the new drugs, 50% of them are actually biological products. Well, in Indonesia, more than 250 pharmaceutical companies, we only have three biopharmaceutical companies. This has also created a big problem. Because, if you see in this table, this is actually the World Top 50 best-selling pharmaceuticals, and 56% are already biopharmaceutical. While in Indonesia, from the Top 100, only two are actually biological product. What happened? It creates a big highlight that in Indonesia, in terms of standard care, it’s still very low. So, this is where Etana comes to play. We want to actually improve the health care in Indonesia by providing affordable quality biological products. Not only we’re going to focus on Indonesia, after we build our production facility, we’re also going to ASEAN countries, and also to the OIC, Organization of Islamic Cooperation, where they’ve got like 57 countries with 1.9 billion people.
Indonesia is emerging from health care. Now we have almost 300 million people. Because we already have the health reimbursement, all people in Indonesia now have access to health care. Because of the government. This really creates a big difference in Indonesia. Because of the pandemic situation in the globe, we understand that it was very hard before to actually import some of the key products. This is the reason why Indonesia, through our personal job, we created a lot of regulations to promote local production. Basically, if you want to do local production in Indonesia, government would like to support. The national government will just buy products first locally produced in Indonesia. If they don’t have it, then they can actually buy imports. It actually creates a lot of opportunities in Indonesia for local production. Of course, I mean, in terms of complexity in businesses, it is still quite difficult. It is still ranked the world’s No. 2 in terms of complexity. While the businesses we are doing, biopharmaceutical, is actually characterized by high tech and high R&D investment and requires knowledge and expertise. This is the reason why we need to work with companies mostly from China or South Korea, who can actually provide training and give us technology transfer, so that we can actually produce it in Indonesia.
Because the government has big changes in terms of promoting local manufacturing of pharmaceutical products, it creates a big opportunity. Once you produce in Indonesia, the government will just buy it. Not only they will buy it, they can also put this product into the national health reimbursement for the use in all the public hospitals. So, it does create big changes in the industry.
What does Etana want? What are we doing? We’re producing a lot of biopharmaceutical products. We focus on vaccines. We focus on therapeutics. We’re going to make every single biopharmaceutical product less imported in Indonesia, locally produced in Indonesia. Working a lot with Chinese companies, working with South Korean companies, do technology transfer, put the factory in Indonesia, and then distribute not only just in Indonesia but also in Southeast Asian countries. These are the three big goals that we are going to have. We already completed the mRNA production facility; we’re building another one for adenovirus, working with a Chinese company called CanSino; and we’re also building Indonesia’s biggest mammalian cell production facility in Indonesia for producing oncology products and hormone products with Innovent.
Last but not least, because Indonesia is a Muslim country, we do care making sure that the product produced in our facility is halal, or qingzhen, how you call it in China. This will make our people in Indonesia feel secure to actually consume the products, and this is also creating an opportunity for us to export to all the Islamic nations all over the world.
Thank you so much for the opportunity. Very good to see you in Guangzhou.
欢迎来到亚洲青年领袖论坛官网